PneumoADIP : Accelerating Access to Pneumococcal Vaccines to Protect the World's Most Vulnerable Children

Contact us

PneumoADIP

We are a dedicated team at the Johns Hopkins Bloomberg School of Public Health, supported by GAVI, focused on improving child health globally. Our mission is to expedite the development and availability of life-saving solutions for pneumococcal diseases, ensuring faster access for the world’s most vulnerable children. By working closely with both the public and private sectors, we aim to create sustainable, affordable solutions that address the health needs of the poorest populations.


Expediting Access to Life-Saving Pneumococcal Solutions for the World's Poorest Children: 

The Pneumococcal Vaccines Accelerated Development and Introduction Plan (PneumoADIP) is a groundbreaking initiative based at the Johns Hopkins Bloomberg School of Public Health. Supported by a $30 million award from the Global Alliance for Vaccines and Immunization (GAVI) and its partner, the Vaccine Fund (VF), PneumoADIP works to address a critical global health challenge: ensuring early access to life-saving interventions for the world’s most impoverished children.

This innovative program takes a unique approach by partnering with the private sector to share risks and secure a more sustainable, affordable supply of life-saving solutions. The goal is to reach the most vulnerable populations by overcoming barriers to access and ensuring that these solutions are made available where they are needed the most.

The PneumoADIP team, composed of six dedicated professionals, operates within the flexible and supportive environment of Johns Hopkins, a leader in global health research. Through this collaboration, PneumoADIP is paving the way for a healthier future by speeding up the introduction of critical health tools, ultimately improving the well-being of children in the world’s poorest countries.

PneumoADIP Approach : 

​

 

PneumoADIP adopts a collaborative and risk-sharing approach with both the private and public sectors. This strategy ensures the earliest access to essential health interventions by partnering with manufacturers to create a sustainable and affordable supply of pneumococcal solutions. The program aims to make these solutions widely accessible and affordable for the poorest populations worldwide, thereby reducing the health disparities between high- and low-income countries. By focusing on efficiency and cost-effectiveness, PneumoADIP is transforming the future of child health, one vaccine at a time.

 

As 436 clients before you, let’s work together